RSV is on the rise in New Jersey, with certain counties experiencing higher levels of the highly contagious respiratory illness. According to the Centers for Disease Control and Prevention, the Respiratory Syncytial Virus (RSV) is causing concern, especially for vulnerable populations. While it typically leads to mild symptoms similar to the common cold, RSV can cause severe illness in babies, older adults, and those with compromised immune systems. The virus is a leading cause of childhood illness and hospitalization for infants. In the United States, RSV season typically begins in the fall and peaks during winter. In New Jersey, emergency room visits and hospital admissions for RSV have been increasing since early October, with over half of the state's counties reporting 'high' or 'very high' levels of RSV cases. The virus accounts for 0.5% of all emergency department visits in the U.S. and 0.7% in New Jersey, according to the latest CDC data. As of January 31, 304 hospitalizations were attributed to RSV across the state, with the majority involving children under 4 and adults over 65. The CDC highlights the vulnerability of infants, noting that two to three out of every 100 infants under 6 months are hospitalized with RSV annually. Tragically, between 100 and 300 children die from RSV each year. To protect infants from severe RSV, the CDC recommends a vaccine for pregnant women or an antibody administered to the baby, though most infants won't require both. The antibody, clesrovimab or nirsevimab, is a monoclonal antibody injection that prevents severe RSV disease in infants and young children. It is recommended for infants under 8 months, especially those born during or entering their first RSV season. Public health experts also advise vaccination for specific groups, including individuals aged 50 to 74 with chronic heart or lung disease, certain chronic medical conditions, and residents of nursing homes or long-term care facilities, as well as everyone aged 75 and older. A single dose of the RSV vaccine provides protection for at least two years, according to the CDC. As of December 2025, vaccination coverage among adults aged 75 and older was 43.4%, while those aged 50-74 at increased risk of severe disease had a coverage of 30.6%. This information highlights the importance of understanding and addressing the impact of RSV in New Jersey, particularly for vulnerable populations.
